Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGIRI versus irinotecan in metastatic gastro-oesophageal adenocarcinoma
2018-002374-46Phase 2Terminated
- Sponsor
- Unicancer
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of regorafenib and irinotecan in gastroesophageal junction adenocarcinoma (2 arms), sponsored by Unicancer. Primary endpoint: Overall survival. Started Aug 2018; status: terminated.
02
Drugs
regorafenibirinotecan
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2018-002374-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002374-46.